Börsipäev 29. juuni
Kommentaari jätmiseks loo konto või logi sisse
-
Pärast kahte koledamat sessiooni, toimus eile USA ja Euroopa aktsiaturgudel põrge. Turuosalised on närvilisematel aegadel taas lootmas keskpankade abile. Fedi intressimäärade futuuride järgi hakati pärast Brexitit arvestama võimalusega, et USA keskpank võib järgnevatel kohtumistel intressimäära koguni langetada ning järgmist tõstmist peetakse tõenäolisemaks alles 2018. aastal. Stoxx Europe 600 indeks rallis 2,6% ning S&P 500 tõusis 1,8%. Suuremate tõusjate seas olid Itaalia pangad, kui Euroopa Komisjon ning Itaalia võimud kaaluvad riigi pangandussektorile abi andmise võimalust.
Eile avaldatud USA esimese kvartali lõplik SKP näitas, et maailma suurim majandus kasvas 1,1% varem arvatud 0,8% asemel. Pettumuseks oli küll suurima komponendi, tarbijate kulutuste kasvu kärpimine varasemalt välja käidud 1,9% pealt 1,5% peale. Tegu on viimase kahe aasta aeglaseima kasvuga. Seda aitasid kompenseerida parem netoeksport, ettevõtete investeeringud ja kasumid. USA tarbijausaldusindeks tõusis 98 punktini ehk viimase kaheksa kuu kõrgeimale tasemele. Küsitletud olid tuleviku osas optimistlikud, oodates järgmise poole aasta jooksul palkade kasvu.
Tänasesse makrokalendrisse mahuvad Hispaania ja Saksamaa esialgsed juunikuu inflatsiooninäitajad ning USA tarbijate maikuu sissetulekute ja kulutuste statistika.
10:00 Hispaania tarbijahinnaindeks (juuni, esialgne)
12:00 Eurotsooni tarbijate usaldusindeks (juuni)
15:00 Saksamaa tarbijahinnaindeks (juuni, esialgne)
15:30 USA tarbijate sissetulekud ja kulutused (mai)
17:00 Pooleliolevate kinnisvaratehingute arv (mai)
17:30 USA naftavarude muutus -
Hispaania tarbijahinnaindeks alanes juunis võrreldes aastatagusega 0,9% oodatud 1% asemel.
-
Suurt muutust eurotsooni majandussentimendis juunis ei toimunud, kui indeks langes 0,2 punkti võrra 104,4 punktile. Kindlustunne suurenes enim tööstusettevõtete seas, samas kui teenusepakkujate ning jaemüüjate meeleolu oli negatiivsem. Tarbijate kindlustunde komponent vähenes 0,3 punkti võrra, kui küsitletud olid vähem mures töökaotuse pärast, kuid nende hinnang tuleviku majandustingimuste ning säästude osas oli nõrgem. Vastused küsimustele koguti enne UK referendumit.
-
USA tarbijate sissetulekute kasv oodatust madalam, kuid kulutuste kasv prognoositust kõrgem:
May Personal Spending M/M +0.4% vs +0.3% Briefing.com consensus
May Personal Income M/M +0.2% vs +0.3% Briefing.com consensus
May PCE Prices- Core M/M +0.2% vs +0.2% Briefing.com consensus -
Gapping up
In reaction to strong earnings/guidance: MCK +2%, GIS +1.7%, SHLM +1.6%, CAMP +0.5%, (also authorizes $25 mln share repurchase)
M&A news: PVTB +23% (PrivateBancorp to be acquired by CIBC (CM) for $18.80 in cash & 0.3657 of a CIBC common share), DRII +18.2% (headlines the company may be near a deal to be acquired by Apollo), OLED +5% (Universal Display acquires the OLED Intellectual Property assets of BASF SE (BASFY) for ~EUR 87 mln), ETE +3.4% (Williams Cos merger with Energy Transfer (ETE) terminated), CM +2.4% (PrivateBancorp to be acquired by CIBC (CM) for $18.80 in cash & 0.3657 of a CIBC common share), WMB +1.7% (Williams Cos merger with Energy Transfer (ETE) terminated), TSLA +1.6% (CtW Investment Group urges Tesla's Board to form a special committee to review SolarCity (SCTY) acquisition and other governance reforms), AA +1.4% (files initial form 10 registration statement for separation of upstream business, Alcoa Corporation)
Select metals/mining stocks trading higher: GFI +6.1%, HMY +4.5%, AG +4.4%, SBGL +4.3%, PAAS +4.2%, AU +3.7%, SLV +3.1%, RIO +3%, KGC +1.8%
Select oil/gas related names showing strength: BCEI +7.1%, WLL +4.4%, CHK +3.5%, PBR +3.2%, OAS +2.9%, BP +2.7%, TOT +2.6%
Other news: TSRO +73.9% (announces that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival), BPMX +27.1% (announces topline results from its Phase 2a safety study of BPX-01), IBIO +18.2% (granted orphan designation by the FDA for the its compound for the treatment of systemic sclerosis), UQM +16.1% (signs definitive stock issuance and purchase agreement with Hybrid Kinetic Group), AMRS +15.8% (Amyris and Ginkgo Bioworks partner; partnership is expected to generate over $300 million in incremental value for both companies over the next 5 years), CLVS +12.1% (trading higher in sympathy with other biotech peers), CTRV +11.5% (ContraVir Pharma and Center Point Clinical Services renew partnership agreemen), ATNM +11% ( initiates pivotal Phase 3 clinical trial for lead asset Iomab-B), MYGN +7.3% (announces its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib), CGIX +7.1% (announces that it offers Ventana PD-L1 assay as a complementary diagnostic IHC test for Genentech's (RHHBY) Tecentriq), KMPH +6.5% ( announces results from a Phase 1 proof-of-concept trial with KP511; KP511 clinical data consistent with preclinical animal data ), BSTG +6.2% (submits application to the FDA seeking oprhan designation for its Cellspan Esophageal Implants), FUEL +3.9% (continued strength after CNBC reported intraday that presidential candidate Donald Trump was using Rocket Fuel's software to track potential supporters behavior), SHPG +3.5% (announces positive topline results of SHP465 efficacy and safety study in adults with ADHD), DRNA +2.8% (announces that new preclinical data shows the potential of Dicerna Galxc subcutaneous delivery platform as Rnai drug discovery enging), BT +2.6% (provides revised financials reflecting previously announced organizational change), LC +2% (Bloomberg detailed comments from today's annual meeting, in which CEO Scott Sanborn disclosed that an investor has started buying $1 bln in debt while others wrap up their due diligence ), GILD +1.3% (Diplomat Pharmacy announces it will dispense Gilead's EPCLUSA for the treatment of patients with chronic hepatitis C virus infection)
Analyst comments: DAR +3.6% (upgraded to Buy from Neutral at Goldman), RIG +2.4% (upgraded to Hold from Sell at Evercore ISI), HZNP +2% (initiated with an Outperform at BMO Capital), NICE +1.5% (resumed with a Overweight at JP Morgan)
Gapping down
In reaction to disappointing earnings/guidance: ECR -12.4%, (updates on its operations, provides FY16 capex & production guidance; announced that it has commenced an underwritten public offering of 37,500,000 shares of its common stock), AVAV -7.9%, AYI -2.7%
M&A news: HTCH -7.4% (Hutchinson Tech. updates on status of acquisition by TDK Corporation, says the FTC is continuing its review and has not indicated when its review may be completed)
Select EU financial related names showing weakness: LYG -2%, RBS -1.7%, DB -1.7%, CS -0.9%
Other news: LPCN -52.2% (receives CRL from the FDA regarding its NDA for LPCN 1021), ESPR -32.1% (provides clinical development and regulatory update for Bempedoic Acid; on track to initiate global pivotal Phase 3 studies and CVOT in Q4 ), ECR -12.8% (offering of 37.5 mln shares of its common stock at $3.50 per share), ALV -4.9% (confirms in statement to Reuters its involvement in Toyota's (TM) Prius recall), HR -4.1% (prices offering of 8 mln shares of common stock for gross proceeds of $268 mln), ANTH -2.3% (provides clinical program updates for Blisibimod and Sollpura, says positive trends from BRIGHT-SC proof-of-concept study and study will continue), BUFF -1.0% (prices secondary offering of 15 mln shares common stock by selling stockholders at $22/share), SWN -1.0% (commences 75 mln common stock offering)
Analyst comments: AEG -2.2% (downgraded to Underweight from Equal Weight at Barclays)
Briefing.com
